Other obesity due to excess calories
Methodology & AI Transparency ⓘ
Other obesity due to excess calories Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Other obesity due to excess calories (E66.09) in Weight & Metabolism relies on resting metabolic rate in Other obesity due to excess calories (E66.09: context), guiding step-wise therapeutic adjustments toward ALT & Fasting in Other obesity due to excess calories (E66.09: Triglycerides) (ALT < 25 U/L; TG < 100 mg/dL (E66.09)).
- 2 Real-world patient consensus: Diagnostic registry E66.09: Other obesity due to excess calories is managed within Weight & Metabolism.
- 3 Typical cash cost range: Differential triage of Other obesity due to excess calories (E66.09) utilizes resting metabolic rate in Other obesity due to excess calories (E66.09: context).
- 4 Top reported side effects / signs: Key Weight & Metabolism biomarkers for Other obesity due to excess calories (E66.09): HOMA-IR Insulin Resistance in Other obesity due to excess calories (E66.09: Index) & ALT & Fasting in Other obesity due to excess calories (E66.09: Triglycerides) (ALT < 25 U/L; TG < 100 mg/dL (E66.09)).
Ask our AI Specialists anything about Other obesity due to excess calories
What Is Other obesity due to excess calories?
Clinical triage of Other obesity due to excess calories (E66.09) in Weight & Metabolism relies on resting metabolic rate in Other obesity due to excess calories (E66.09: context), guiding step-wise therapeutic adjustments toward ALT & Fasting in Other obesity due to excess calories (E66.09: Triglycerides) (ALT < 25 U/L; TG < 100 mg/dL (E66.09)).
Pathophysiology, Underlying Causes & Clinical Presentation
Other obesity due to excess calories (E66.09) alters weight & metabolism homeostasis through TNF-alpha) [Other obesity due to excess calories E66.09]; clinical remission targets ALT & Fasting in Other obesity due to excess calories (E66.09: Triglycerides) within ALT < 25 U/L; TG < 100 mg/dL (E66.09).
Common Symptoms & Clinical Signs
- • Presentation of Other obesity due to excess calories (E66.09): daytime sluggishness or in Other obesity due to excess calories (E66.09: loud snoring linked)
- • Secondary Other obesity due to excess calories clinical sign: central abdominal visceral in Other obesity due to excess calories (E66.09: fat accumulation resistant)
- • Symptom flares in Other obesity due to excess calories correlating with HOMA-IR Insulin Resistance in Other obesity due to excess calories (E66.09: Index) deviation outside < 1.4 (E66.09)
- • Functional weight & metabolism impact requiring resting metabolic rate in Other obesity due to excess calories (E66.09: context) evaluation (E66.09)
Other obesity due to excess calories Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E66.09 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Other obesity due to excess calories (E66.09: Index) | < 1.4 (E66.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Other obesity due to excess calories (E66.09: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E66.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Other obesity due to excess calories (E66.09: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E66.09) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other obesity due to excess calories
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Intralipid (I.V. Fat Emulsion) Intralipid • RxCUI 805131 | Lipid Emulsion | 86% | $1.2800 | $ 100.66 /mo |
| Lacura Blemish Dots Conceal and Treat (Salicylic Acid 0.5%) Lacura Blemish Dots Conceal and Treat • RxCUI 1994404-B56136181 | FDA Prescription Therapeutic Agent | 79% | $4.9868 | $ 367.55 /mo |
| Phentermine and Topiramate Extended-Release Phentermine and Topiramate Extended-Release Generic • RxCUI 1302827 | Sympathomimetic Amine Anorectic | 75% | $2.8476 | $ 123.83 /mo |
| I.V. Fat Emulsion Intralipid • RxCUI 200318 | Lipid Emulsion | 85% | $2.5900 | $ 113.39 /mo |
| Orforglipron Foundayo • RxCUI 2739844 | GLP-1 Receptor Agonist | 79% | $20.6637 | $ 185.00 /mo |
| Tesamorelin Egrifta Sv, Egrifta Wr • RxCUI 1044587 | FDA Prescription Therapeutic Agent | 80% | $1.0800 | $ 52.24 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other obesity due to excess calories)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other obesity due to excess calories Patient Community & “People Like Me” Threads
Filter Other obesity due to excess calories community threads and patient logs by age, biological sex, dosage, and treatment duration.